Compare SMTI & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | EU |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 306.9M |
| IPO Year | 2008 | 2011 |
| Metric | SMTI | EU |
|---|---|---|
| Price | $33.26 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $35.00 | $2.87 |
| AVG Volume (30 Days) | 161.6K | ★ 5.4M |
| Earning Date | 11-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | ★ N/A | N/A |
| Revenue | $15,586,976.00 | ★ $43,155,000.00 |
| Revenue This Year | $13.07 | $59.92 |
| Revenue Next Year | $14.23 | $23.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $0.77 |
| 52 Week High | $35.52 | $3.68 |
| Indicator | SMTI | EU |
|---|---|---|
| Relative Strength Index (RSI) | 23.14 | 32.82 |
| Support Level | $20.32 | $0.77 |
| Resistance Level | $34.36 | $1.47 |
| Average True Range (ATR) | 0.53 | 0.07 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 57.42 | 5.83 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.